Immunity 2024

Cordyceps militaris beverage and the immune response in healthy adults: a randomized controlled trial

A Thai RCT: healthy volunteers (10 men and 10 women) received a fermented C. militaris beverage with 2.85 mg cordycepin or placebo for 8 weeks. NK-cell activity rose in men by week 4 (p=0.049) and in women by week 8 (p=0.023); IL-1β fell in men, IL-6 in women. Liver, kidney and blood safety markers were unchanged.

Sci Rep 2024. A randomized controlled clinical trial examining the effects of Cordyceps militaris beverage on the immune response in healthy adults (PMID 38580687).

Rationale

Cordyceps militaris products are popular as "immune boosters", yet human clinical data were scarce. Researchers in Phayao (Thailand) developed a submerged-fermentation functional beverage (FCM) and tested its effects on immune markers and safety in healthy volunteers.

Methods

Randomized placebo-controlled trial: 20 healthy adults (10 men, 10 women) received FCM containing 2.85 mg cordycepin or a placebo daily for 8 weeks. At baseline, week 4 and week 8 they measured immune cell markers (NK-cell activity), immunoglobulins, cytokines and standard safety panels (hepatic, renal, hematological, glucose, lipids).

Results

  • NK-cell activity increased significantly in men by week 4 on FCM (p=0.049) and in women by week 8 (p=0.023) versus baseline.
  • Within-group analysis: IL-1β decreased in men (p=0.049), IL-6 decreased in women (p=0.047).
  • Glucose, lipid profile and safety indices did not differ between groups — no liver, kidney or blood toxicity was detected.

Conclusions

The authors conclude that FCM is a candidate immune-boosting supplement without hepato-, nephro- or hematotoxicity. The key functional signal is increased NK-cell activity (natural killers — key effectors of antiviral immunity) with different dynamics in men and women.

Caveats

  • Tiny sample (n=20, 10 per sex): the effect needs confirmation in larger RCTs; the sex differences may be chance at this n.
  • Surrogate markers measured (NK activity, cytokines), not clinical outcomes (URI frequency, severity) — a link to real "cold resistance" is unproven.
  • The product is a submerged-fermentation beverage with a known cordycepin dose (2.85 mg), not fruiting bodies or an arbitrary powder: results cannot be extrapolated to any "cordyceps supplement".
  • This card replaces an unverifiable citation about a "12-week Cs-4 antioxidant RCT" previously placed here — no such work exists in PubMed; the current source was verified directly.